Autochthonous peruvian natural plants as potential SARS-CoV-2 Mpro main protease inhibitors

Resum

Over 750 million cases of COVID-19, caused by the Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2), have been reported since the onset of the global outbreak. The need for effective treatments has spurred intensive research for therapeutic agents based on pharmaceutical repositioning or natural products. In light of prior studies asserting the bioactivity of natural compounds of the autochthonous Peruvian flora, the present study focuses on the identification SARS-CoV-2 Mpro main protease dimer inhibitors. To this end, a target-based virtual screening was performed over a representative set of Peruvian flora-derived natural compounds. The best poses obtained from the ensemble molecular docking process were selected. These structures were subjected to extensive molecular dynamics steps for the computation of binding free energies along the trajectory and evaluation of the stability of the complexes. The compounds exhibiting the best free energy behaviors were selected for in vitro testing, confirming the inhibitory activity of Hyperoside against Mpro, with a Ki value lower than 20 µM, presumably through allosteric modulation

Tipus de document

Article


Versió publicada

Llengua

Anglès

Publicat per

MDPI

Documents relacionats

Reproducció del document publicat a: https://doi.org/10.3390/ph16040585

Pharmaceuticals, 2023, vol. 16, num. 4, p. 1-20

https://doi.org/10.3390/ph16040585

Citació recomanada

Aquesta citació s'ha generat automàticament.

Drets

cc-by (c) Peralta-Moreno, Maria Núria et al., 2023

https://creativecommons.org/licenses/by/4.0/